



Spermosens receives patent approval in Canada

Spermosens AB ("Spermosens" or the "Company") today announces that the patent "Biosensor for Male Infertility" (CA 3,109,529) has been granted in Canada. The patent covers the company's unique method for measuring sperm binding to the egg receptor JUNO — a critical biological interaction during fertilization that no existing test can evaluate.

The patent granted in Canada further strengthens Spermosens' intellectual property portfolio, which already includes granted patents in key markets including Europe, United States of America, Japan, South Korea, Australia, South Africa, Hong Kong and Singapore. The protection covers both the method and system underlying the JUNO-*Checked* technology, providing long-term exclusivity for the company's approach to assessing critical sperm function.

Tore Duvold, CEO of Spermosens, comments: *"Canada is an interesting market for innovative solutions to improve fertility diagnostics and treatment. The granted patent in Canada represents another important step in securing our global IP position for JUNO-Checked. Canada has a well-developed fertility sector, and the growing demand for improved diagnostic tools supports the relevance of our technology. JUNO-Checked provides a completely novel way to assess sperm-egg interaction — a key factor that cannot be measured with today's standard tests."*

About JUNO-Checked

JUNO-*Checked* is a patented diagnostic technology developed by Spermosens to assess the ability of sperm cells to bind to the JUNO receptor on the egg — a crucial step in fertilization. This interaction cannot be evaluated with conventional semen analysis. By replicating this process in vitro, JUNO-*Checked* provides a direct, functional measurement of sperm-egg binding, offering new insight for the assessment of male fertility.

About the Canadian Market

Infertility affects around 15–20% of couples in Canada, with male factors contributing to about half of all cases. Canada's total fertility rate decreased to 1.33 children per woman in 2022. The fertility services market, including IVF clinics and ART procedures, was valued at approximately EUR 686 million in 2023 and is growing steadily. Diagnostic semen analysis, performed in IVF clinics, sperm banks and IVD laboratories, represents a market of about EUR 70 million, highlighting the addressable segment for JUNO-*Checked*. Recent policy changes in Quebec and British Columbia are expanding publicly funded fertility services, reflecting growing societal support for access to fertility care.

References

- Grand View Research – Fertility Services Market Report (Canada):
<http://www.grandviewresearch.com/horizon/outlook/fertility-services-market/canada>
- ASD Reports – Canada Semen Analysis Market Forecast 2024–2032:
<http://www.asdreports.com/market-research-report-675760/canada-semen-analysis-market-forecast>
- Quebec Medically Assisted Reproduction Program Changes (March 2024):
<http://www.quebec.ca/en/family-and-support-for-individuals/pregnancy-parenthood/assisted-reproduction/medically-assisted-reproduction-program>
- British Columbia Publicly Funded IVF Program (Effective April 2025):
<http://www2.gov.bc.ca/gov/content/health/accessing-health-care/publicly-funded-ivf-program>

For further information, please contact

Tore Duvold, CEO

Email: info@spermosens.com

Spermosens AB is a pioneering biotechnology company based in Sweden, focused on advancing fertility diagnostics through science driven solutions. The company develops cutting-edge technologies designed to improve fertility outcomes and streamline treatment pathways for individuals and couples facing infertility. The proprietary product, *JUNO-Checked*, provides a novel diagnostic approach that enhances precision and evaluations by measuring the sperm-egg binding capacity. *JUNO-Checked* supports more informed clinical decisions and individualized treatments strategies. Driven by a strong commitment to scientific excellence and patient care, Spermosens collaborates with leading research institutions to deliver transformative fertility diagnostics to the global market. The company's shares are listed on the Spotlight Stock Market under the name SPERM (ISIN code SE0015346424). For more information, see www.spermosens.com